ריספפר 1 מ"ג

Country: Iżrael

Lingwa: Ebrajk

Sors: Ministry of Health

Ingredjent attiv:

RISPERIDONE 1 MG

Disponibbli minn:

PHARMALOGIC LTD

Kodiċi ATC:

N05AX08

Għamla farmaċewtika:

FILM COATED TABLETS

Rotta amministrattiva:

PER OS

Manifatturat minn:

SPECIFAR S.A., GREECE

Grupp terapewtiku:

RISPERIDONE

Indikazzjonijiet terapewtiċi:

Risperidone is indicated for the management of schizophrenia and manifestation of psychotic disorders. The antipsychotic efficacy of Risperidone was established in short-term (6 to 8 weeks) controlled trials of schizophrenic inpatients. Risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Risperidone is indicated for the treatment of psychotic manifestations of dementia. Conduct and other disruptive disorders: Treatment of behavioral disorders expressed by impulse control disorders or self-alienated-aggressive or treatment- requiring behavioral disorders with reduced or substandard intelligence. Treatment should not be given to children under the age of 5 years. Risperidone is indicated for the treatment of mania in bipolar disorder. These episodes are characterized by symptoms such as elevated expansive or irritable mood inflated self-esteem decreased need for sleep pressured speech racing thoughts distract

Data ta 'l-awtorizzazzjoni:

2011-03-01